<p>All parameters are median (IQR) unless otherwise stated.</p><p>cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted and unboosted); NRTI – nucleoside reverse transcriptase inhibitor.</p><p>*Others included injecting drug use, transfusion and unrecorded.</p><p>PIs included Atazanavir (boosted and unboosted) (5%), Lopinavir/Ritonavir (11%), Indinavir (boosted and unboosted) (32%), Nelfinavir (27%), Ritonavir (10%), Saquinavir (boosted and unboosted) (13%), Tipranavir (1%), Fosamprenavir (1%); NNRTIs included Delavirdine (1%), Efavirenz (44%), Nevirapine(55%);</p
<p>*Study phase, genotype/CD4 eligibility restrictions, pills and doses per day were significant on ...
*<p>81% ARV-experienced patients in the study; LLOQ = Lower limit of quantitation; 3TC = Lamivudine;...
M (IQR), Mean (interquartile range). ATVrtv, atazanavir boosted with ritonavir. ATV400, unboosted-at...
<p><sup>a</sup>Patients in HAART treatment were using combinations of nucleoside reverse transcripta...
a<p>Values are expressed as No. (%) or median (interquartile range).</p>b<p>Standardized T scores ba...
<p>cART, combination antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; PMTCT, ...
<p>IQR: Interquartile range; MSM: Men who have Sex with Men; MTC: Mother to Child Transmission; AZT:...
a<p>Values represent n (% with characteristic) or median (interquartile range).</p>b<p>Patient had a...
<p>* values are n (%) unless otherwise indicated.</p><p><sup>a</sup> at enrolment in HIV care.</p><p...
<p>ART: antiretroviral therapy, ATV: atazanavir, DRV: darunavir, EFV: efavirenz, ETR: etravirine, FT...
<p>All parameters expressed as median and (interquartile range) unless indicated. HALS = HIV-1/HAART...
<p>HD, healthy donors; NT, not tested;</p><p>* HIV therapy: pt1: lamivudine, zidovudine, nevirapine;...
<p>VL, plasma HIV-1 RNA viral load; (c)ART, (combination) anti-retroviral therapy; AZT, zidovudine; ...
<p>ART, antiretroviral therapy; AZT, zidovudine; CRF, circulating recombinant form; d4T, stavudine; ...
<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use...
<p>*Study phase, genotype/CD4 eligibility restrictions, pills and doses per day were significant on ...
*<p>81% ARV-experienced patients in the study; LLOQ = Lower limit of quantitation; 3TC = Lamivudine;...
M (IQR), Mean (interquartile range). ATVrtv, atazanavir boosted with ritonavir. ATV400, unboosted-at...
<p><sup>a</sup>Patients in HAART treatment were using combinations of nucleoside reverse transcripta...
a<p>Values are expressed as No. (%) or median (interquartile range).</p>b<p>Standardized T scores ba...
<p>cART, combination antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; PMTCT, ...
<p>IQR: Interquartile range; MSM: Men who have Sex with Men; MTC: Mother to Child Transmission; AZT:...
a<p>Values represent n (% with characteristic) or median (interquartile range).</p>b<p>Patient had a...
<p>* values are n (%) unless otherwise indicated.</p><p><sup>a</sup> at enrolment in HIV care.</p><p...
<p>ART: antiretroviral therapy, ATV: atazanavir, DRV: darunavir, EFV: efavirenz, ETR: etravirine, FT...
<p>All parameters expressed as median and (interquartile range) unless indicated. HALS = HIV-1/HAART...
<p>HD, healthy donors; NT, not tested;</p><p>* HIV therapy: pt1: lamivudine, zidovudine, nevirapine;...
<p>VL, plasma HIV-1 RNA viral load; (c)ART, (combination) anti-retroviral therapy; AZT, zidovudine; ...
<p>ART, antiretroviral therapy; AZT, zidovudine; CRF, circulating recombinant form; d4T, stavudine; ...
<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use...
<p>*Study phase, genotype/CD4 eligibility restrictions, pills and doses per day were significant on ...
*<p>81% ARV-experienced patients in the study; LLOQ = Lower limit of quantitation; 3TC = Lamivudine;...
M (IQR), Mean (interquartile range). ATVrtv, atazanavir boosted with ritonavir. ATV400, unboosted-at...